The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
This month’s newsletter features novel research from our RADR® AI platform and lays a foundation for how AI can be applied to discover new indications for cancer drugs in record times and at significantly reduced costs.
The NCI’s CellMinerCDB platform contains large scale multi-omic drug response data from over 20,000 experiments and was leveraged to uncover novel aspects of Lantern’s drug candidates LP-184 and LP-100, including:
Following the CellMinerCDB insights, Lantern scientists developed a highly predictive RADR® ML model, “10 gene model,” to predict LP-184’s potency for ATRT using publicly available patient gene expression data:
Why it matters: Rare cancers like ATRT often have little data and limited research funds, leaving a void in therapy options for these patients. These results demonstrate both the power and adaptability of AI and ML and provide a new source of hope in potential treatment options for ATRT.
The big picture: Using an AI and ML forward approach, novel targeted therapies can be developed for other rare and ultra-rare pediatric cancers with no standard-of-care therapies and urgent clinical needs.
RADR®’s LP-184 ATRT predictions were strengthened by validation in cell and animal model wet lab experiments:
Why it matters: Cell and mouse model experiments are critical to validating AI predictions and can be an indicator of how a drug will respond in patients. Both RADR® AI predictions and preclinical experiments point to LP-184 being a promising drug candidate for ATRT.
